



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/798,339	03/12/2004	Masahiro Kakehi	250307US0DIV	6720

22850	7590	08/27/2007
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.		
1940 DUKE STREET		
ALEXANDRIA, VA 22314		

EXAMINER	
SLOBODYANSKY, ELIZABETH	

ART UNIT	PAPER NUMBER
1652	

NOTIFICATION DATE	DELIVERY MODE
08/27/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary	Application No.		Applicant(s)	
	10/798,339		KAKEHI ET AL.	
	Examiner		Art Unit	
	Elizabeth Slobodyansky, PhD		1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 August 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 9 and 11-14 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 9 and 11-14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 13, 2007 has been entered.

The amendment filed on August 13, 2007 amending claim 9, 11 and 12 has been entered.

Claims 9 and 11-14 are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 9, 13 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thaller et al. alone or in view of Cowman et al.

Thaller et al. (form PTO-1449 filed March 12, 2004, reference AAB) teach the sequence of the *aphA* gene (page 193, Figure 1). They further characterize 5'-nucleotidase activity of the *E. coli* AphA enzyme (page 195, Table 1). They teach that

Art Unit: 1652

another 5'-nucleotidase in *E. coli* is UshA (page 197, 2nd column, last paragraph). They suggest producing strains carrying aphA mutations (page 198).

Cowman et al. (form PTO-1449 filed March 12, 2004 , reference AAA) teach the ushA gene from *E. coli* encoding a 5'-nucleotidase.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to produce *E. coli* mutants having non-functional, for example, disrupted *ushA* gene and *aphA* gene. The motivation to produce such mutants is provided by Thaller et al. who teach 5'-nucleotide dephosphorylating activity of *ushA* gene and *aphA* gene. Mutants with disrupted *ushA* gene and *aphA* gene would have a higher yield of 5'-nucleotides. One of ordinary skill in the art at the time the invention was made would have a reasonable expectation of success because the structures of both *ushA* gene and *aphA* gene were known at the time the invention was made and methods for disrupting known genes were widely used.

Claims 9 and 11-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thaller et al. alone or in view of Cowman et al. and further in view of Matsui et al.

The teachings of Thaller et al. and Cowman et al. are outlined above.

Matsui et al. (EP 1004 663 A1, form PTO-1449 filed March 12, 2004, reference AP) teach a method for producing purine nucleosides such as inosine and guanosine which are important as intermediate compounds for synthesis of 5'-inosinic acid and 5'-guanylic acid (page 2, [001], lines 5-7). They teach a microorganism which acquired the purine nucleoside-producing ability because of an increase of an activity of an enzyme

Art Unit: 1652

involved in the purine nucleoside biosynthesis due to its gene overexpression (page 2, [0007]). They teach that enzyme can be PRPP amidotransferase that is desensitized (page 2, [0008]). They teach the mutation Lys326Glu in PRPP amidotransferase gene (*purF*) resulting in desensitizing the feedback inhibition (page 6, [0055]; page 10, [0076])) and *E. coli* comprising said mutant PRPP amidotransferase (page 11). They further teach that in order to efficiently utilize the *purF* gene, it can be used with other genes involved in the IMP biosynthesis such as IMP dehydrogenase gene (*guaB*) and GMP synthase gene (*guaA*) (page 7, [0064]).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to produce *E. coli* mutants having non-functional, for example, disrupted *ushA* gene and *aphA* gene thus preventing the decomposition of inosine 5'-phosphate ester and guanosine 5'-phosphate ester and additional genes such as *purF*, *guaA* and *guaB* that increase their production. The motivation to produce such mutants is provided by Thaller et al. who teach 5'-nucleotide dephosphorylating activity of *ushA* gene and *aphA* gene and Matsui et al. who teach the role of *purF*, *guaA* and *guaB* in the nucleotide biosynthesis. One of ordinary skill in the art at the time the invention was made would have a reasonable expectation of success because the structures of all involved genes were known at the time the invention was made and methods for mutation of known genes were widely used.

Response to Arguments

Applicant's arguments filed August 13, 2007 have been fully considered but they are not persuasive.

With regard to the 103(a) rejection, Applicants argue that "The rejections of the claims under 35 U.S.C. § 103(a) over Thaller, Cowman and Matsui set forth at pages 7-9 of the Office Action are respectfully traversed. The cited references, alone or in any combination, suggest that decreasing expression of *ushA* gene and *aphA* gene by mutating or disrupting the *ushA* gene and the *aphA* gene substantially eliminates the 5'-nucleotidase activity in the periplasm, as claimed. This effect is shown at page 31 of the specification. That result would not have been predicted from the cited references and establishes the patentability of the claimed method" (Remarks, page 5). This is not persuasive because it appears obvious that if the genes responsible for the activity are disrupted, said activity would be substantially eliminated.

The rejection of the claims under 35 U.S.C. §112, 1st and 2nd paragraphs, are withdrawn in view of the amendment.

Conclusion

This is an RCE of applicant's earlier Application No. 10/798,339. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL**

Art Unit: 1652

even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky, PhD whose telephone number is 571-272-0941. The examiner can normally be reached on M-F 10:00 - 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, PhD can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


Elizabeth Slobodyansky, PhD